interferon alfa
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Alpheon | — | 2006-09-05 | europa.eu ↗ |
Trials 59 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 20 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 29 trials | ||||||
| Phase 2 | NCT02340962 Background | May 2015 → Aug 2016 | chronic hepatitis C virus infection | TaiGen Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00719264 Comparator | Nov 2008 → Dec 2011 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00619268 Comparator | Feb 2008 → Feb 2012 | renal cell carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT00520403 Background | Sep 2007 → Mar 2010 | renal cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00433069 Background | Jan → Dec 2007 | chronic hepatitis C virus infection | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 2 | NCT00308607 Background | Aug 2005 → Dec 2008 | metastatic melanoma | University of Turku | Completed | No outcome recorded |
| Phase 2 | NCT00117637 Comparator | Jun 2005 → Sep 2006 | renal cell carcinoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00110058 Background | Feb 2005 → Jul 2006 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003727 Background | Mar 1999 → Mar 2005 | leukemia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06079879 Comparator | Dec 2023 → Jul 2027 expected | essential thrombocythemia | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01094964 Background | Oct 2009 → Oct 2013 | urinary bladder cancer | Cancer Research Campaign Clinical Trials Centre | Unknown | No outcome recorded |
| Phase 3 | NCT00631371 Comparator | Apr 2008 → Apr 2012 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00167583 Comparator | Nov 2004 → Dec 2014 | Behcet disease, panuveitis, retinal vasculitis | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 3 | NCT00204529 Comparator | Oct 2004 → May 2013 | melanoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 3 | NCT00083889 Comparator | Aug 2004 → Sep 2008 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00738530 Background | Jun 2004 → Sep 2008 | renal cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00381953 Comparator | Feb 2003 → Apr 2006 | chronic hepatitis C virus infection | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 3 | NCT00002737 Background | Mar 1996 → Jan 2001 | kidney cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00172809 Comparator | Jul 2005 → Jun 2006 | chronic hepatitis C virus infection, end stage renal failure | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03733652 Comparator | Nov 2018 → Sep 2021 | chronic hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-10-28 | Novartis Pharmaceuticals | Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a novartis.com ↗ |
| 2012-02-23 | Vertex Pharmaceuticals Incorporated | Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C vrtx.com ↗ |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C vrtx.com ↗ |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗ |
| 2006-04-29 | Vertex Pharmaceuticals Incorporated | Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients vrtx.com ↗ |
| 2006-01-09 | Vertex Pharmaceuticals Incorporated | VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon vrtx.com ↗ |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 87 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon-alfa | “temsirolimus plus bevacizumab versus interferon alfa (IFN) plus bevacizumab in metastatic renal cell carcinoma (mRCC).” PMID 24297945 ↗ Dec 201340“The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown.” PMID 15010373 ↗ Mar 2004 |
| Known as | alpha interferon | “two cytokine treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate chance of response in metastatic renal cell carcinoma.” NCT00291369 ↗ |
| Known as | Human Serum ALbumin/interferon alpha2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01997944 ↗ |
| Known as | IFN | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗5“two cytokine treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate chance of response in metastatic renal cell carcinoma.” NCT00291369 ↗ “temsirolimus plus bevacizumab versus interferon alfa (IFN) plus bevacizumab in metastatic renal cell carcinoma (mRCC).” PMID 24297945 ↗ Dec 2013 “The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown.” PMID 15010373 ↗ Mar 2004 “Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC.” PMID 20368558 ↗ Apr 2010 “bevacizumab, interferon alfa-2a (IFN)” NCT00719264 ↗ |
| Known as | IFN alfa | “6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week” NCT00065468 ↗ |
| Known as | IFN alfa-2a | “To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in...” NCT00000754 ↗ |
| Known as | IFN-A | “interferon alfa (IFN-A) subcutaneously (SC) daily beginning after WBC reduction” NCT00002771 ↗ |
| Known as | IFN-A2a | “To evaluate the anti-HIV effect of single agent versus combination therapy with zidovudine (AZT) and interferon alfa-2a (IFN-A2a), as measured by p24 protein expression, viral...” NCT00000696 ↗3“To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS.” NCT00000687 ↗ “The two kinds are interferon alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A).” NCT00001113 ↗ “The two kinds are interferon alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A).” NCT00000725 ↗ |
| Known as | IFN-alpha | “Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC.” PMID 20368558 ↗ Apr 2010 |
| Known as | IFN-alpha-2a | “combination treatment with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFN-alpha-2a) was superior to IFN-alpha-2a alone” PMID 15961764 ↗ Jun 20051“interferon alfa-2a (IFN-alpha-2a) in patients with untreated, advanced renal cancer.” PMID 19171708 ↗ Jan 2009 |
| Known as | IFN-α | “a daily nasal spray of interferon-alpha (IFN-α) would reduce the incidence of COVID-19 or community-acquired respiratory viral infections in adult cancer patients.” PMID 40874769 ↗ Feb 20263“CALGB 90206 was a phase III trial of 732 patients with metastatic renal cell carcinoma (mRCC) comparing bevacizumab plus IFNα (BEV + IFN) with IFNα alone (IFN).” PMID 34965953 ↗ Jul 2022 “Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens” NCT04072263 ↗ “imatinib 400 mg/d plus interferon alfa (IFN-α; n = 351)” PMID 21422420 ↗ Mar 2011 |
| Known as | IFN-α2a | “This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral...” NCT03209219 ↗1“rituximab combined with 5 weeks of interferon-α2a (IFN-α2a) (3-4.5 MIU daily) as priming.” PMID 25686644 ↗ Mar 2015 |
| Known as | Interferon | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗ |
| Known as | Interferon Alfa ; IFN、 | “Interferon Alfa ; IFN、” NCT01834963 ↗ |
| Known as | interferon alfa-2a | “the effect of interferon alfa-2a (3 megaunits three times per week for 2 years or until recurrence) on overall survival (OS) and recurrence-free survival (RFS) was compared...” PMID 14665609 ↗ Dec 200327“Arm II (recombinant interferon alfa-2a): Patients receive recombinant interferon alfa-2a subcutaneously (SC) 3 times weekly for 12 weeks.” NCT00416429 ↗ “combination treatment with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFN-alpha-2a) was superior to IFN-alpha-2a alone” PMID 15961764 ↗ Jun 2005 “in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma.” NCT01609010 ↗ “1.2.1 Interferon Alfa 2a Interferon Alfa was the first drug shown to have bioactivity against HCV.” NCT00502970 ↗ “interferon alfa-2a (IFN-alpha-2a) in patients with untreated, advanced renal cancer.” PMID 19171708 ↗ Jan 2009 |
| Known as | interferon alpha-2A (recombinant) | “The two kinds are interferon alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A).” NCT00000725 ↗ |
| Known as | Interferon alpha2 a | “We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period.” NCT00508040 ↗8“interferon-alpha-2a (1), 9 MU given subcutaneously three times per week, once per week for 6 weeks.” PMID 12074329 ↗ May 2002 |
| Known as | Interferon-2A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01404936 ↗ |
| Known as | interferon-a-2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01609010 ↗ |
| Known as | Interferon-alpha | “a daily nasal spray of interferon-alpha (IFN-α) would reduce the incidence of COVID-19 or community-acquired respiratory viral infections in adult cancer patients.” PMID 40874769 ↗ Feb 20262“Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha” NCT01834963 ↗ “Interferon-alpha (IFN-alpha) is a standard initial cytokine therapy in RCC” PMID 15102658 ↗ Apr 2004 |
| Known as | INTERFERON-ALPHA-n1 | “INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002868 ↗1“INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002869 ↗ |
| Known as | interferon-α2a | “rituximab combined with 5 weeks of interferon-α2a (IFN-α2a) (3-4.5 MIU daily) as priming.” PMID 25686644 ↗ Mar 2015 |
| Known as | Peg-interferon alpha-2a | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗ |
| Known as | PEGASYS | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗1“PEG-IFN-α2a) (PegasysTM, Roche Pharma Schweiz AG, Reinach, Switzerland) 180 μg QW” NCT00433069 ↗ |
| Known as | recombinant interferon alfa | “Biological: recombinant interferon alfa” NCT00098618 ↗1“Biological: recombinant interferon alfa” NCT00072046 ↗ |
| Known as | Recombinant Interferon Alfa 2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02829775 ↗ |
| Known as | Roferon | “Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub...” NCT00065468 ↗1“Interferon alfa 2a [Roferon]” NCT00738530 ↗ |
| Known as | Roferon-A | “The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with...” NCT00308607 ↗ |
| Known as | WELLFERON | “INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002868 ↗1“INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002869 ↗ |
| Action | Inhibit | “IFN alfa-2a inhibits translation of viral proteins.” NCT00000754 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Alpha-2A Interferon” NCT00000687 ↗ |
| Route | Subcutaneous | “IFN-A2a is administered as a single subcutaneous injection once a day.” NCT00000687 ↗ |